Binnopharm Group Increases Production Of Drugs Against COVID-19

Binnopharm Group Increases Production Of Drugs Against COVID-19
Binnopharm Group Increases Production Of Drugs Against COVID-19

Video: Binnopharm Group Increases Production Of Drugs Against COVID-19

Отличия серверных жестких дисков от десктопных
Video: Antiviral drugs and biologics to treat and prevent SARS COV-2 infection 2023, February
Anonim

The pharmaceutical holding Binnopharm Group, which is part of AFK Sistema, has, on average, doubled the production volumes of the five antibacterial drugs most demanded against the background of the coronavirus pandemic to 10.6 million packages for 9 months of 2020. As stated in a press release received on Friday, November 13, in the editorial office of Gazeta.Ru, we are talking about Azithromycin, Levofloxacin, Linezolid, Meropenem and Moxifloxacin. These drugs are included in the list recommended by the Russian Ministry of Health for the treatment and prevention of COVID-19. “We are doing our best to promptly respond to the needs of the Russian healthcare system for the necessary drugs,” said Rustem Muratov, General Director of Binnopharm Group. According to him, the company's production sites are loaded to the maximum. So, for 9 months of 2020, the volume of production of the antibiotic "Azithromycin" has grown seven times year-on-year, and the volume of production of "Levofloxacin" has doubled. "For us, the production of drugs for the treatment of COVID-19 is a socially significant job, an opportunity to contribute to the fight against the pandemic," Muratov said. The Ministry of Health of the Russian Federation has updated the recommendations for doctors on the prevention, diagnosis and treatment of coronavirus infection on October 1, 2020 and now recommends the use of about 60 generic drug names for this, all of which are included in the list of vital and essential medicines. In total, 24 drug names from the list of the Ministry of Health are produced at the Binnopharm Group sites, and this is the largest Russian portfolio of drugs recommended for the treatment of COVID-19 among domestic manufacturers.

Popular by topic